

Amendments to the Claims:

This listing of claims will replace all prior versions of claims in the application.

**Listing of Claims:**

1. (currently amended) A bilayer thin film comprising:
  - (a) a rapidly dissolving film layer including a top outer surface and a bottom outer surface wherein the film layer comprises at least one softener; and
  - (b) a powder matrix coating on at least one of said outer surfaces of said film layer comprising at least one composition selected from the group consisting of oils herbs, and tree and plant components and extracts.
2. (withdrawn) A method of treating a patient that has a cough, comprising the steps of
  - (a) preparing at least one dissolvable film layer including a film forming composition and free of oils, herbs, tree and plant components and extracts, and medicants; and
  - (b) administering said film layer in the mouth of the patient to dissolve at least a portion of said film layer.
3. (currently amended) A bilayer composition comprising:
  - a rapidly dissolving film layer, wherein the film layer comprises at least one softener; and
  - a powder matrix coating, wherein the coating is applied to at least one side of the film layer; ~~and~~
  - ~~a medicant.~~

4. (cancelled)
5. (cancelled)
6. (currently amended) The composition of claim [[4]] 3 wherein the film layer, the powder matrix coating, or both comprise ~~comprises the~~ a medicant.
7. (previously presented) The composition of claim 6 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents, periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents, tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.
8. (previously presented) The composition of claim 6 wherein said medicant comprises a cough curing agent.
9. (previously presented) The composition of claim 6 wherein the medicant comprises a sore throat treatment agent.
10. (previously presented) The composition of claim 6 wherein the powder matrix comprises an auxiliary dissolution control composition.

11. (previously presented) The composition of claim 10 wherein the auxiliary dissolution control composition comprises one or more of carrageenan, gelatin alginates, pullulan, PVP, cyclodextrin, calcium, or fibers.
12. (previously presented) The composition of claim 6 wherein the powder matrix comprises an absorption composition.
13. (previously presented) The composition of claim 12 wherein the absorption composition comprises one or more of carboxymethylcellulose, pectin, modified starches, gelatin, or carrageenan.
14. (previously presented) The composition of claim 6 wherein the powder matrix comprises an adhesive.
15. (previously presented) The composition of claim 11 wherein the adhesive comprises one or more of poorly water soluble cellulose derivatives including ethyl cellulose, cellulose acetate and butyl cellulose, shellac, or fatty acids including steric acid and palmitic acid.
16. (previously presented) The composition of claim 6 wherein the powder matrix further comprises a mucosa adherent.
17. (previously presented) The composition of claim 16 wherein the mucosal adherent is selected from one or more of carboxymethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, sodium alginate, methylcellulose, hydroxyl propyl cellulose, hydroxypropylmethyl cellulose, polyethylene glycols, carbopol, polycarbophil, carboxyvinyl copolymers, propylene glycol alginate, alginic acid,

methyl methacrylate copolymers, tragacanth gum, guar gum, karaya gum, ethylene vinyl cetate, dimethylpolysiloxanes, polyoxyalkylene block copolymers or hydroxyethylmethacrylate copolymers.

18. (previously presented) The composition of claim 6 wherein the powder matrix comprises a flow agent.

19. (previously presented) The composition of claim 18 wherein the flow agent is a lipid, wax or polyol.

20. (previously presented) The composition of claim 6 wherein the powder matrix comprises a bulking agent.

21. (previously presented) The composition of claim 20 wherein the bulking agent comprises one or more of avicel, sugar alcohols including manitol, sorbitol, xylitol and isomalt, lactic sugar, sorbitol dextrin, starch, anhydrous calcium phosphate, calcium carbonate, magnesium trisilicate, silica or amylase.

22. (previously presented) The composition of claim 6 wherein the powder matrix further comprises one or more of a bulking agent, filler, pigment, flavoring agent, or sweetener.

23. (previously presented) The composition of claim 6 wherein the powder matrix comprises less than about 10% water by weight.

24. (previously presented) The composition of claim 6 wherein the thickness of the film layer is in the range of about 0.01 mm to about 3 mm.

25. (previously presented) The composition of claim 6 wherein the thickness of the film layer is in the range of about 0.03 mm to about 1 mm.
26. (previously presented) The composition of claim 6 further comprising a layer applied over the coating.
27. (previously presented) The composition of claim 6 wherein the film layer comprises at least two layers.
28. (currently amended) A bilayer composition comprising:  
a film layer comprising at least one softener, wherein the film layer rapidly dissolves in an oral cavity; and  
a powder matrix coating ~~comprising a medicant~~ wherein the coating is applied to at least one side of the film layer.
29. (currently amended) The composition of claim 28 wherein ~~the coating comprises a powder matrix~~ the film layer, the powder matrix coating, or both comprise a medicant.
30. (previously presented) The composition of claim 29 wherein the film layer dissolves within thirty seconds of being placed in the oral cavity.
31. (previously presented) The composition of claim 29 wherein the film layer dissolves within 15 seconds of being placed in the oral cavity.
32. (previously presented) The composition of claim 31 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral

sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents, periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents, tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.

33. (previously presented) The composition of claim 31 wherein said medicant comprises a cough curing agent.

34. (previously presented) The composition of claim 31 wherein said medicant comprises a sore throat treatment agent.

35. (previously presented) The composition of claim 31 wherein the film layer comprises one or more of pullulan, modified starch, pectin, carageenan, a maltodextrin or alginate.

36. (previously presented) The composition of claim 31 wherein the film layer comprises a natural or synthetic water soluble polymer.

37. (previously presented) The composition of claim 36 wherein the polymer comprises one or more of hydroxypropyl cellulose, methyl cellulose, hydroxypropyl alkylcellulose, carboxymethyl cellulose or the salt of carboxymethylcellulose.

38. (previously presented) The composition of claim 36 wherein the polymer comprises an acrylic acid copolymer or its sodium, potassium or ammonium salt.

39. (previously presented) The composition of claim 29 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents, periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents, tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.

40. (previously presented) The composition of claim 29 wherein said medicant comprises a cough curing agent.

41. (previously presented) The composition of claim 29 wherein the medicant comprises a sore throat treatment agent.

42. (currently amended) A bilayer composition comprising:  
a film layer comprising at least one softener, wherein the film layer rapidly dissolves in an oral cavity; and  
a coating comprising a powder matrix;  
wherein the coating is applied to at least one side of the film layer and wherein the powder matrix comprises a medicant, an adhesive, a bulking agent, a flow agent, and a sweetener.

43. (previously presented) The composition of claim 42 wherein the film layer dissolves within thirty seconds of being placed in the oral cavity.

44. (previously presented) The composition of claim 42 wherein the film layer dissolves within fifteen seconds of being placed in the oral cavity.
45. (previously presented) The composition of claim 42 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents, periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents, tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.
46. (previously presented) The composition of claim 42 wherein said medicant comprises a cough curing agent.
47. (previously presented) The composition of claim 42 wherein the medicant comprises a sore throat treatment agent.
48. (previously presented) The composition of claim 42 wherein the medicant comprises benzocaine or menthol or a combination thereof.
49. (previously presented) The composition of claim 42 wherein the adhesive comprises carboxymethylcellulose powder or carrageenan or a combination thereof, the bulking agent comprises modified food starch, and the flow agent comprises talc.



50. (withdrawn) A method of manufacturing a rapidly dissolving thin film comprising the steps of:
- providing a film layer;
  - applying a coating to said film layer wherein said coating comprises a powder matrix.
51. (withdrawn) The method of claim 50 wherein the film layer dissolves within thirty seconds of being placed in an oral cavity.
52. (withdrawn) The method of claim 50 wherein the film layer dissolves within fifteen seconds of being placed an the oral cavity.
53. (withdrawn) The method of claim 52 wherein the powder matrix comprises a medicant.
54. (withdrawn) The method of claim 53 further comprising the step of drying the film layer and powder matrix.
55. (withdrawn) The method of claim 54 wherein the step of drying comprises the steps of curing and heating.
56. (withdrawn) The method of claim 54 wherein the powder matrix comprises a flow agent and wherein the step of drying is at a temperature at about the softening point of the flow agent.
57. (withdrawn) The method of claim 56 wherein the flow agent comprises a lipid, wax or polyol.

58. (withdrawn) The method of claim 53 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents, tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.

59. (withdrawn) The method of claim 53 wherein said medicant comprises a cough curing agent.

60. (withdrawn) The method of claim 53 wherein the medicant comprises a sore throat treatment agent.

61. (withdrawn) The method of claim 52 wherein the film layer comprises a medicant.

62. (withdrawn) The method of claim 61 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents,

tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.

63. (withdrawn) The method of claim 61 wherein said medicant comprises a cough curing agent.

64. (withdrawn) The method of claim 61 wherein the medicant comprises a sore throat treatment agent.

65. (withdrawn) The method of claim 53 further comprising the step of preparing the coating in a fluidized bed.

66. (withdrawn) The method of claim 65 wherein the coating is applied by sifting, screening, atomization, static or mechanical agitation.

67. (withdrawn) The method of claim 65 wherein the powder particles are charged.

68. (withdrawn) The method of claim 65 wherein the coating is applied using a static spray gun.

69. (withdrawn) The method of claim 68 wherein the static spray gun charges the powder particles such that the powder particles adhere to the surface of the film layer.

70. (withdrawn) The method of claim 53 further comprising:  
mixing the powder matrix with a liquid carrier to form a particle liquid solution wherein the coating is applied to the film layer by spraying the liquid solution on the film layer and evaporating the liquid carrier.

71. (withdrawn) A method of manufacturing a rapidly dissolving thin film comprising the steps of:
- providing a film layer;
  - applying a coating to said film layer wherein the coating comprises a powder matrix and wherein the powder matrix comprises a medicant, an adhesive, a bulking agent, a flow agent, and a sweetener.
72. (withdrawn) The method of claim 71 wherein the film layer dissolves within fifteen seconds of being placed in the oral cavity.
73. (withdrawn) The method of claim 72 further comprising the step of drying the film layer and powder matrix.
74. (withdrawn) The method of claim 73 wherein the step of drying is at a temperature at about the softening point of the flow agent.
75. (withdrawn) The method of claim 74 wherein the flow agent comprises a lipid, wax or polyol.
76. (withdrawn) The method of claim 72 wherein said medicant is selected from the group consisting of anti-inflammatory steroids, anti-inflammatory anodynes, anti-inflammatory enzymes, antihistamine agents, oral sterilizing agents, antibiotics, chemically therapeutic agents, cardiac strengthening agents, blood vein dilating agents, local narcotic agents, cough curing agents, sore throat and mouth treatment agents periodontal disease treatment agents, digesting organ curing agents, anti-diabetic agents, other enzymes, blood pressure depressing agents,

tranquilizers, styptic agents, sexual hormones, and agents for curing virulent carcinoma or ulcers.

77.(withdrawn) The method of claim 72 wherein said medicant comprises a cough curing agent.

78.(withdrawn) The method of claim 72 wherein the medicant comprises a sore throat treatment agent.

79.(withdrawn) The method of claim 72 further comprising the step of preparing the coating in a fluidized bed.

80.(withdrawn) The method of claim 72 wherein the coating is applied by sifting, screening, atomization, static or mechanical agitation.

81.(withdrawn) The method of claim 79 wherein the powder particles are charged.

82.(withdrawn) The method of claim 79 wherein the coating is applied using a static spray gun.

83.(withdrawn) The method of claim 82 wherein the static spray gun charges the powder particles such that the powder particles adhere to the surface of the film layer.

84.(new) The bilayer composition of claim 3 wherein, the softener is a polyalcohol.

85.(new) The bilayer composition of claim 84, wherein the polyalcohol is selected from the group consisting of glycerol, polyethylene glycol, propylene glycol, and glycerol monoesters with fatty acids.

86.(new) The bilayer composition of claim 85, wherein the amount of glycerol in the film layer is about 0.1 to 5% (w/w).

87.(new) The bilayer composition of claim 86, wherein the amount of glycerol in the film layer is about 2 to 4% (w/w) and the powder matrix coating prevents the bilayer composition from sticking to another bilayer composition.

88.(new) A plurality of bilayer compositions according to the composition of claim 87, wherein each bilayer composition comprises a film layer, wherein the amount of glycerol in the film layer is about 2 to 4% (w/w) and the powder matrix coating prevents a first bilayer composition from sticking to a second bilayer composition.